Bcr-Abl
Bcl-Abl is a constitutively activated chimeric tyrosine kinase which is the genetic abnormality expressed in patient with CML (chronic myeloid leukemia).
-
Summary: a tyrphostin that targets transforming Bcr-Abl fusion proteins -
Summary: receptor tyrosine kinases inhibitor -
Summary: Type II Bcr-Abl inhibitor -
Summary: BCR-ABL inhibitor -
Target: FLT3|Bcr-Abl|Tie-2|KDRSummary: Bcr-Abl inhibitor -
2 CitationSummary: Bcr-Abl/Lyn tyrosine kinase inhibitor -
Target: Bcr-AblSummary: Bcr-Abl inhibitor,novel orally bioavailable -
Target: Bcr-Abl|SrcSummary: Dual Src/Abl kinase inhibitor, ATP-competitive, -
Target: Abl kinasesSummary: Abl kinases inhibitor -
Summary: P210bcr/abl tyrosine kinase inhibitor